Given the demonstrated ability of ITE to suppress LPS-induced MMP-9 expression through the inhibition of NF-κB and AP-1 signaling, future studies will explore its therapeutic potential in in vivo models of obesity-associated inflammation. This evidence concerns the gene NFKB1 and obesity disorder.